Two new pretrial orders were issued in late September for the Xarelto MDL. If you or a loved one have been injured by Xarelto, contact us immediately.BloodThinnerHelp.com reports today on two new orders issued for the Xarelto multidistrict litigation. On September 17, 2015, the United States District Court in the Eastern District of Louisiana, where the MDL is consolidated, issued the second Case Management Order, the full text of which can be found here. The court also issued Pretrial Order 15A, which was an order in regards to the preservation of emails, text messages, and instant messages. Pretrial Order 21 was also issued which established document production protocol for the litigation. More information on the two Pretrial Orders can be found here. For more detailed information on the Xarelto lawsuits, visit this page.
Xarelto Lawsuits Consolidated in MDL
The Xarelto MDL was formed in December 2014 after a motion was made to consolidate the rising number of cases against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. These cases were able to be consolidated because they all made similar allegations against the same defendants, specifically that Xarelto causes serious uncontrollable internal bleeding events which lead to severe injuries and that the manufacturers of Xarelto were aware of the dangers of the drug and failed to adequately warn both doctors and patients about these dangers.
Xarelto was initially released onto the United States market in 2011 after approval from the Food and Drug Administration, (FDA) to treat atrial fibrillation, deep vein thrombosis, and to be used in patients who have undergone hip and knee replacement surgeries. The manufacturers heavily marketed Xarelto as a convenient alternative to the traditional blood thinner Warfarin, stating that Xarelto users did not need frequent blood monitoring and did not have to follow a strict diet that Warfarin requires. Advertisements for the drug could be found in magazines, on television with commercials starring well known athletes and public figures, and also in highly respected medical journals. Xarelto sales skyrocketed in the initial months. Despite these conveniences, the lawsuits allege that Xarelto is a much more dangerous drug than other blood thinners on the market.
Xarelto's Serious Side Effects
Xarelto works differently than traditional blood thinners because it blocks the chemical in the blood that is responsible for making the blood clot, thrombin. By blocking thrombin, Xarelto competently takes away the blood's ability to clot on its own. This is dangerous because there is no antidote for the effects of Xarelto, meaning that in the event of an internal bleeding emergency, there is no way to reverse the drug's anticoagulant effects. The lack of antidote has led to Xarelto users experiencing uncontrollable internal bleeding, which can lead to even more serious injuries and even death.
"We strongly urge anyone who has been harmed by Xarelto to contact us immediately." Xarelto attorney Marc Goldich said, "Now that the Xarelto litigation is moving forward, we expect to see even more cases filed in the MDL."
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.